NY-COTY
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin Klein ETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITY fragrance portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/
Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire)
Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnering with an authentic couple with a deep connection to the brand. The advertising campaign will be featured globally and supported by digital, social, print, and TV.
“Calvin Klein’s ETERNITY campaigns have always shown love that was intimate and real. It’s an honor to have our romance recognized for its authenticity, and have our commitment captured in this campaign. We are excited to be a part of ETERNITY’s iconic, timeless love story,” said Idris and Sabrina jointly.
CALVIN KLEIN ETERNITY AROMATIC ESSENCE FOR MEN and FOR WOMEN are elevated and bold aromatic fragrances, connected by a unique coconut note.
ETERNITY AROMATIC ESSENCE FOR MEN is a highly contrasted aromatic gourmand, crafted by principal perfumers Daphné Bugey and Frank Voelkl of Firmenich. The fragrance opens with fresh juniper berry essence with woody and gin-like facets. At the heart, the radiance of cardamom adds a spicy quality balanced by a sweet and floral lavender note. The seductive warmth of comforting coconut adds a sexy gourmand twist.
ETERNITY AROMATIC ESSENCE FOR WOMEN is a fresh, floral gourmand, created by perfumers Véronique Nyberg and Julie Massé of Mane. The captivating composition’s powerful freshness puts a modern twist on a floral fragrance. It opens with aromatic floral hints of lavender. At the heart, a sparkling coconut water accord unveils a vibrant gourmand, contrasted by an alluring dry down of sensual woods at the base.
The fragrances’ signature bottles and outer cartons have been reimagined with elevated codes and luxurious finishes. Inspired by the vibrancy of gemstones, the scents are housed in lacquered teal green glass bottles. Maintaining the shape and silver cap of the iconic original ETERNITY fragrances, the updated packaging exudes sensuality.
About Idris and Sabrina Elba
Idris Elba is an award-winning actor, producer, director, and musician continually securing his place as one of the most versatile performers in Hollywood. In 2016, he became the first male actor to receive dual SAG awards in one evening - Outstanding Performance by a Male Actor in a Supporting Role and Outstanding Performance in a TV Movie or Miniseries.
A multi-hyphenate in every sense of the word Sabrina Elba is not only a model, entrepreneur, and UN Goodwill Ambassador for the International Fund for Agricultural Development (IFAD) but also works with various civil society orgs like Farm Africa, Conservation International, and the European board for Global Citizen, receiving accolades like the TIME100 Impact award and the Crystal Award from the World Economic Forum.
About Calvin Klein
Calvin Klein is one of the world’s leading global fashion lifestyle brands with a history of bold, non-conformist ideals that inform everything we do. Founded in New York in 1968, the brand’s minimalist and sensual aesthetic drives our approach to product design and communication, creating a canvas that offers the possibility of limitless self-expression. The Calvin Klein brands – CK Calvin Klein, Calvin Klein, Calvin Klein Jeans, Calvin Klein Underwear, and Calvin Klein Performance – are connected by the intention and purpose of elevating everyday essentials to globally iconic status. Each of the brands has a distinct identity and position in the retail landscape, providing us the opportunity to market a range of universally appealing products to domestic and international consumers with a variety of needs. Our products are underpinned by responsible design, high-quality construction, and the elimination of all unnecessary details. We strive for unique and dimensional pieces that continuously wear well and remain relevant season after season. Global retail sales of Calvin Klein products were approximately $9.3 billion in 2022.
Calvin Klein continues to solidify its position as an innovator of emerging digital platforms and modern marketing campaigns. PVH acquired Calvin Klein in 2003 and continues to oversee a focused approach to growing the brand’s worldwide relevance, presence, and long term growth.
About Coty Inc.
Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. We serve consumers around the world, selling prestige and mass market products in more than 125 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.
ADVERTISING CREDITS:
Creative Direction: Calvin Klein
Campaign Videos: Mert Alas
Advertising Campaign Images: Mert Alas
EDITORIAL CREDIT:
TERNITY AROMATIC ESSENCE FOR WOMEN CALVIN KLEIN
ETERNITY AROMATIC ESSENCE FOR MEN KLEIN
SOCIAL MEDIA: #CKEternity
BRAND HANDLE: @calvinklein
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301420936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom